Pilocarpine Arecoline Muscarine
Pilocarpine Arecoline Muscarine - Related Videos
03:50
Systemic Pilocarpine Treatment: Mouse Model of Temporal Lobe Epilepsy
0 Views •
2023
This video presents the procedure for inducing status epilepticus (SE) in mice by systemic administration of pilocarpine to model temporal lobe epilepsy.
01:25
Cholinergic Receptors: Muscarinic
0 Views •
2023
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
07:09
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
0 Views •
Cited by 7 •
2011
We describe procedures for repeated administration of inhibitors of muscarinic signaling to the levator auris longus (LAL) muscle of young adult mice and for subsequent immunostaining of its neuromuscular junctions (NMJs) in wholemounts. The LAL muscle has unique advantages for revealing in vivo pharmacological effects on NMJs.
01:20
Antiasthma Drugs: Muscarinic Receptor Antagonists
0 Views •
2024
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways. Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
13:34
Assessment of Memory Function in Pilocarpine-induced Epileptic Mice
0 Views •
Cited by 4 •
2020
This article presents experimental procedures for assessing memory impairments in pilocarpine-induced epileptic mice. This protocol can be used to study the pathophysiologic mechanisms of epilepsy-associated cognitive decline, which is one of the most common comorbidities in epilepsy.
FAQs
These compounds produce effects by activating muscarinic acetylcholine receptors, which belong to the G protein-coupled receptor family. Receptor stimulation changes signaling in parasympathetic target tissues and can modify glandular secretion, smooth-muscle activity, heart rate, or pupil diameter. The observable response depends on which tissue receives the signal and how strongly that tissue is affected.
A shared receptor mechanism does not guarantee identical physiological outcomes. Receptor selectivity, dose, and tissue distribution influence the intensity and location of signaling. Consequently, Pilocarpine, Arecoline, and Muscarine can differ in their effects or adverse responses even though all mimic acetylcholine at muscarinic receptors. These variables are central to interpreting pharmacological comparisons.
Dose influences how strongly muscarinic receptors are stimulated, while tissue distribution determines which parasympathetic targets experience that stimulation. Together, these factors shape changes in secretion, smooth-muscle activity, heart rate, and pupil diameter. They also help explain why increasing or differently distributed exposure can shift a response from a useful pharmacological effect toward unwanted or toxic effects.
Pilocarpine has therapeutic applications in glaucoma and dry mouth because its muscarinic activity can produce useful parasympathetic effects in selected tissues. Its clinical relevance illustrates how receptor activation may be harnessed rather than studied only as a physiological phenomenon. At the same time, the same signaling properties require attention to tissue responses and possible adverse effects.
Arecoline and Muscarine serve as research examples for examining muscarinic receptor signaling, autonomic physiology, and cholinergic toxicity. Their value lies in revealing how parasympathetic receptor activation translates into tissue responses and harmful effects. Studying them alongside Pilocarpine helps investigators separate general muscarinic principles from differences related to dose, receptor selectivity, and tissue distribution.
A useful comparison focuses on the receptor-mediated response produced by each compound, the tissues affected, and the relationship between exposure and outcome. Researchers can examine changes in glandular secretion, smooth-muscle activity, heart rate, and pupil diameter, then consider whether differences reflect selectivity, dose, or distribution. This framework connects observed physiology with therapeutic and toxicological interpretation.